SCHEMBL3097664

SCHEMBL3097664

CC(C)N(C(=O)C(Cc1ccc(NC(=O)c2ccccc2)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1)c1cccnc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.44
USP30 Q70CQ3 1/20 0.42
GAA P10253 1/20 0.41
LARS1 Q9P2J5 1/20 0.41
NAMPT P43490 1/20 0.41
POLB P06746 1/20 0.41
MMP9 P14780 1/20 0.41
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
ADRB3 P13945 1/20 0.41
IDO1 P14902 1/20 0.40
F2 P00734 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3080311 0.87 LARS1 (0.43) SMN1; SMN2LMNALARS1ADRB2ADRB1
SCHEMBL3080156 0.86 USP30 (0.49) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL3090460 0.85 MMP9 (0.49) NPC1RAB9AMEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL3097618 0.85 SMN1; SMN2 (0.52) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL3103710 0.85 KAT6A (0.47) MEN1KMT2ALMNALARS1POLB
SCHEMBL3103341 0.84 MMP9 (0.48) ALDH1A1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL3100986 0.84 MMP9 (0.44) SMN1; SMN2MEN1KMT2ALMNALARS1
SCHEMBL3093901 0.83 MMP9 (0.46) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL3102970 0.83 MMP9 (0.46) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL3093022 0.82 MMP9 (0.55) NPC1RAB9AMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 ALDH1A1 617/4885SMN1; SMN2 2844/4885NPC1 3306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.